Key Takeaways PFE is set to report Q4 results on Feb. 3, with consensus estimates of $16.93B in sales and$0.57 EPS.PFE's Q4 growth is expected from oncology drugs & Vyndaqel, partly offset by weaker COVID products & Prevnar.PFE faces pressure from IRA-related discounts, declining COVID sales and upcoming patent expirations.Pfizer (PFE) is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is ...